<DOC>
	<DOC>NCT03063762</DOC>
	<brief_summary>This is an open-label, multi-center, randomized, Phase 1b, adaptive, clinical study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary therapeutic activity of RO6874281 in participants with unresectable advanced and/or metastatic RCC. The study will consist of dose-escalation part and extension part.</brief_summary>
	<brief_title>Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Inclusion criteria: Unresectable advanced and/or metastatic RCC with component of clear cell histology and/or component of sarcomatoid histology that has not been previously treated with any systemic therapy, including treatment in the adjuvant setting During dose escalation only, unresectable advanced and/or metastatic RCC with one prior Vascular Endothelial Growth Factor Receptor (VEGFR)Tyrosinekinase inhibitor (TKI) therapy are allowed At least one tumor lesion with location accessible to biopsy per clinical judgment of the treating physician Measurable disease, as defined by RECIST v1.1 Participants with unilateral pleural effusion are eligible if they fulfill both of the following: (a) New York Heart Association (NYHA) Class 1; (b) Global initiative for obstructive lung disease (GOLD) test level 1 (forced expiratory volume in 1 second [FEV1]/ forced vital capacity [FVC] less than [&lt;] 0.7 and FEV1 &gt;= 80 percent [%] predicted) Symptomatic or untreated central nervous system (CNS) metastases Participants with asymptomatic CNS metastases with previous or concomitant brain deficiencies, as defined in the protocol Participants with confirmed bilateral pleural effusion by Xray Episode of significant cardiovascular/cerebrovascular vascular acute disease within 6 months prior to Day 1 of study drug administration Active or uncontrolled infections Known HIV or known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection Positive serology for hepatitis B (any of or both hepatitis B surface antigen [HBsAg] and total hepatitis B core antibody [HBcAb] positive) Major surgery or significant traumatic injury &lt;28 days prior to the first RO6874281 infusion (excluding fine needle biopsies) or anticipation of the need for major surgery during study treatment Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1 Cycle 1 Serious, nonhealing wound; active ulcer; or untreated bone fracture Proteinuria at screening, as demonstrated by a urine protein to creatinine ratio (UPCR) of &gt;=1.0 at screening History or risk of autoimmune disease Chronic use of steroids (including inhaled)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Renal Cell Carcinoma</keyword>
	<keyword>RO6874281</keyword>
	<keyword>Obinutuzumab</keyword>
	<keyword>Atezolizumab</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>